Single infusion may prevent chronic headaches after concussion
NCT ID NCT07191145
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This study tests whether a single infusion of eptinezumab, given within 8 weeks of a mild brain injury, can reduce headache days and prevent short-term post-traumatic headaches from becoming long-term. About 80 adults with migraine-like post-traumatic headaches will receive either the drug or a placebo. The main goal is to see if the drug lowers the number of moderate-to-severe headache days 3 months after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRAUMATIC HEADACHE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
eptinezumab
What this could lead to
If it works, this could provide a quick, single-infusion treatment to prevent short-term post-traumatic headaches from becoming chronic and disabling.
What could go wrong
This is a small, early-phase trial with only 80 people. The drug may not work better than placebo, and side effects like fatigue or nausea could occur.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.